U.S. markets open in 1 hour 16 minutes

  • S&P Futures

    4,480.75
    +5.25 (+0.12%)
     

  • Dow Futures

    35,328.00
    +47.00 (+0.13%)
     

  • Nasdaq Futures

    15,330.00
    +25.50 (+0.17%)
     

  • Russell 2000 Futures

    2,214.80
    +8.20 (+0.37%)
     

  • Crude Oil

    66.55
    +0.91 (+1.39%)
     

  • Gold

    1,805.60
    -0.70 (-0.04%)
     

  • Silver

    23.73
    +0.07 (+0.31%)
     

  • EUR/USD

    1.1743
    -0.0007 (-0.06%)
     

  • 10-Yr Bond

    1.2550
    0.0000 (0.00%)
     

  • Vix

    17.25
    -1.31 (-7.06%)
     

  • GBP/USD

    1.3716
    -0.0007 (-0.05%)
     

  • USD/JPY

    109.6620
    -0.0180 (-0.02%)
     

  • BTC-USD

    49,329.75
    -1,046.44 (-2.08%)
     

  • CMC Crypto 200

    1,249.32
    -14.12 (-1.12%)
     

  • FTSE 100

    7,085.95
    -23.07 (-0.32%)
     

  • Nikkei 225

    27,732.10
    +237.86 (+0.87%)
     

Worldwide Protein Drugs Industry to 2026 - Prevalence of Chronic Diseases is Driving Growth

·5 min read

DUBLIN, Aug. 24, 2021 /PRNewswire/ -- The "Global Markets and Manufacturing Technologies for Protein Drugs 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo
Research and Markets Logo

The global protein drugs market should reach $394.2 billion by 2026 from $265.0 billion in 2021 at a compound annual growth rate (CAGR) of 8.3% for the forecast period of 2021 to 2026.

The monoclonal antibodies segment of the global protein drugs market is expected to grow from $126.7 billion in 2021 to $208.6 billion in 2026 at a CAGR of 10.5% for the forecast period of 2021 to 2026.

The vaccines segment of the global protein drugs market is expected to grow from $35.4 billion in 2021 to $50.4 billion in 2026 at a CAGR of 7.3% for the forecast period of 2021 to 2026.

Report Scope

This report will focus on protein drugs, classification and manufacturing technologies. The protein drugs market can be classified into peptide hormones, monoclonal antibodies, cytokines, therapeutic enzymes, blood factors, vaccines and peptide antibiotics. This report focuses on six techniques for manufacturing protein therapeutics, including fractionation from natural human/animal sources, microbial fermentation, cell culture, chemical synthesis, transgenics and embryonated eggs. The report focuses on each market and its applications, regulatory environment, latest trends and developments, drivers, restraints and challenges affecting the market.

The report covers company profiles for all the major companies and also company share analysis. This report also covers market projections to 2026 and relevant patent analysis. By geography, the market has been segmented into the United States, Europe and emerging markets. Emerging markets include India, China, Japan, Korea, Taiwan, Canada, Africa, Australia and New Zealand. For market estimates, data has been provided for the year 2019, 2020 (as base year) and forecast through 2026.

The Report Includes

  • 37 data tables and 28 additional tables

  • An overview of the global markets and manufacturing technologies for protein drugs

  • Estimation of the market size and analyses of global market trends, with data from 2019 to 2020, estimates for 2021 with projections of compound annual growth rates (CAGRs) through 2026

  • Highlights of the current and future market potential and quantification of protein drugs market based on type, manufacturing process and region

  • Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast

  • A detailed description of protein drugs, their classification and six main manufacturing technologies and information on recombinant deoxyribonucleic acid (rDNA) technology

  • Information on advancements in manufacturing technologies, new product launches of the industry and discussion on the effect of biosimilars entry to the protein drugs market

  • Detailed analysis of the regulatory framework and policies and technological changes within the industry

  • Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies and a relevant patent analysis

  • Comprehensive company profiles of the leading players of the industry, including AbbVie Inc., Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Pfizer Inc. and Sanofi S.A.

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Therapeutic Proteins: Overview

  • History

  • Pharmacological Classification of Therapeutic Proteins

  • Protein Therapeutics with Enzymatic or Regulatory Activity

  • Protein Therapeutics with Special Targeting Activity

  • Protein Vaccines

  • Molecular Classification of Therapeutic Proteins

  • Cytokines

  • Monoclonal Antibodies

  • Blood Products

  • Peptide Antibiotics

  • Vaccines

  • Enzymes

  • Peptide Hormones

  • Manufacturing Technologies

  • Fractionation/Extraction from Natural Sources (Human/Animal)

  • Microbial Fermentation and Bioreactors

  • Transgenics

  • Mammalian Cell Culture

Chapter 4 Regulatory Aspects

  • Monoclonal Antibodies

  • Therapeutic Enzymes

  • Cytokines

  • Peptide Hormones

  • Vaccines

  • Blood Products

  • Peptide Antibiotics

  • Recalls and Safety Alerts

Chapter 5 New Developments

  • Monoclonal Antibodies

  • Vaccines

  • Cytokines

  • Peptide Hormones

  • Therapeutic Enzymes

  • Blood Products

  • Peptide Antibiotics

Chapter 6 Market Analysis of Protein Drugs by Type

  • Global Market for Protein Drugs by Type

  • Market Share

  • Monoclonal Antibodies

  • Peptide Hormones

  • Vaccines

  • Blood Factors

  • Cytokines

  • Therapeutic Enzymes

  • Peptide Antibiotics

Chapter 7 Market Analysis of Protein Drugs by Region

  • Global Market for Protein Drugs by Region

  • Market Share

  • Regional Markets for Monoclonal Antibodies

  • Regional Markets for Peptide Hormones

  • Regional Markets for Vaccines

  • Regional Markets for Blood Factors

  • Regional Markets for Cytokines

  • Regional Markets for Therapeutic Enzymes

  • Regional Markets for Peptide Antibiotics

Chapter 8 Market Analysis of Protein Drugs by Manufacturing Process

  • Global Market for Protein Drugs by Manufacturing Process

  • Market Share

  • Monoclonal Antibodies

  • Peptide Hormones

  • Vaccines

  • Blood Factors

  • Cytokines

  • Therapeutic Enzymes

  • Peptide Antibiotics

Chapter 9 Competitive Landscape

  • Mergers and Acquisitions

  • Monoclonal Antibodies

  • Market Share

  • Peptide Hormones

  • Market Share

  • Vaccines

  • Market Share

  • Blood Factors

  • Market Share

  • Cytokines

  • Market Share

  • Therapeutic Enzymes

  • Market Share

  • Peptide Antibiotics

  • Market Share

Chapter 10 Market Dynamics

  • Market Drivers

  • Prevalence of Chronic Diseases

  • Growing Aging Population

  • Advancements in Manufacturing Technologies

  • New Product Launches

  • Licensing and Collaboration Agreements

  • Market Challenges

  • Price Controls

  • Regulatory Pressures

  • Entry of Biosimilars

  • Impact of COVID-19 on Protein Drugs Market

Chapter 11 Patent Analysis

Chapter 12 Company Profiles

  • Abbvie Inc.

  • Alexion Pharmaceuticals

  • Amgen Inc.

  • Apotex Inc.

  • Bayer Pharmaceuticals

  • Biogen

  • Biomarin Pharmaceutical Inc.

  • Bristol-Myers Squibb

  • Biotest

  • CSL Ltd.

  • Eli Lilly

  • F. Hoffmann-La Roche Ag

  • Fresenius Kabi

  • Glaxosmithkline

  • Grifols S.A.

  • Johnson & Johnson

  • Merck & Co., Inc.

  • Merck Kgaa

  • Novo Nordisk Ag

  • Novartis Ag

  • Octapharma Ag

  • Pfizer Inc.

  • Sandoz

  • Sanofi S.A.

  • Seagen

  • Takeda Pharmaceutical Co., Ltd.

  • UCB Co.

For more information about this report visit https://www.researchandmarkets.com/r/t7qd0e

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

Cision
Cision

View original content:https://www.prnewswire.com/news-releases/worldwide-protein-drugs-industry-to-2026---prevalence-of-chronic-diseases-is-driving-growth-301361480.html

SOURCE Research and Markets

Recommended Stories

  • Why Canoo, Romeo Power, and Velodyne Lidar Are Surging Today

    One, Velodyne Lidar (NASDAQ: VLDR), was rising on new developments in an activist shareholder's battle with company management; Romeo Power (NYSE: RMO) and Canoo (NASDAQ: GOEV), by contrast, were up sharply on no apparent news -- but they (and Velodyne) may have been undergoing short squeezes. Canoo was up by about 26.7%. Romeo Power was up by about 16.1%.

  • 3 Big Dividend Stocks Yielding at Least 8%; RBC Says ‘Buy’

    Market trends are generally heading up, and investors are feeling confident. The S&P 500 has gained 20% so far this year, and the NASDAQ has gained 15%; for now, it looks like the confidence is justified. The economy’s reopening is proceeding apace, and both investors and consumers are looking forward to a more normal 2022. In a recent note for RBC, the firm’s head of US equity strategy, Lori Calvasina, acknowledges the optimism – and also points out the potential fly in the ointment. Stock perf

  • Why This Online Gambling Stock Is a Buy Right Now

    Paysafe (NYSE: PSFE) announced its second-quarter earnings report on Aug. 16, and investors responded with stern negativity, sending the stock down 15%. Paysafe is the biggest payment processor in iGaming (online gambling), serving some of the world's leading bookmakers and virtual casinos including European-owned Betfair and Pokerstars. It's now breaking into the U.S. market through both new and existing partnerships, and the U.S. has quickly become the company's fastest-growing region.

  • Cathie Wood is Doubling Down on These 10 Stocks

    In this article, we discuss the 10 stocks Cathie Wood is doubling down on. If you want to skip our detailed analysis of these stocks, go directly to Cathie Wood is Doubling Down on These 5 Stocks. Cathie Wood, the chief of New York-based ARK Investment Management, is a trail-blazing investor on Wall Street, who […]

  • 2 Ultra-Yielding Dividend Giants Poised to Raise Dividends

    The Federal Reserve cut its benchmark rate to near zero to deal with COVID-19, and rates across the board have plummeted. Currently, the 30-year U.S. Treasury bond is yielding 1.93%, a figure even lower than during the financial crisis. At the same time, inflation is running above 5%, which means these investors are earning negative real returns and losing purchasing power!

  • Warren Buffett Is Selling These 10 Stocks

    In this article, we discuss the 10 stocks Warren Buffett is selling. If you want to skip our detailed analysis of these stocks, go directly to Warren Buffett Is Selling These 5 Stocks. Warren Buffett, the chief of Nebraska-based Berkshire Hathaway, is often referred to as the “Sage of Omaha” due to his incredibly successful […]

  • China Tech Stocks Rebound as Cathie Wood Joins Bargain Hunters

    (Bloomberg) -- Chinese technology stocks rallied for a second day as bargain hunters returned, emboldened by Tencent Holdings Ltd.’s share buyback and strong results from JD.com, which drew Cathie Wood back into the market.The Hang Seng Tech Index advanced more than 7%, adding to a 2% gain on Monday, after a five-week rout that took the gauge to the lowest level since its inception last year. Heavyweights Tencent and Alibaba Group Holding Ltd. climbed 8.8% and 9.5%, respectively.While there’s no

  • Chip shortage to worsen, Trillium pops 180% after Pfizer buyout, Coinbase reassures on stablecoins

    Yahoo Finance’s Jared Blikre reports on the day's trending tickers.

  • Pinduoduo stock jumps after surprise profit, although revenue comes up short

    Shares of Pinduoduo Inc. jumped 7.1% in premarket trading Tuesday, after the China-based mobile marketplace connecting agricultural producers and consumers reported a surprise second-quarter profit although revenue nearly doubled but missed forecasts. The company swung to net income of RMB2.41 billion ($373.97 million), or RMB1.69 per American depositary share, from a loss of RMB899.35 million, or RMB0.75 per ADS, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share

  • ContextLogic Inc. (NASDAQ:WISH) and the Problems With Cheap User Acquisition

    ContextLogic Inc. (NASDAQ:WISH) has gained a lot of attention recently, and investors are split between thinking that the company has high potential based on gross margins and revenue, and those who are concerned that the bottom has yet to be reached. In this article we will look at the performance, predictions as well as take a look at expenses and see why the market might have such a divergent view on the company.

  • Vaxart, Inc.'s (NASDAQ:VXRT) Shift From Loss To Profit

    Vaxart, Inc. ( NASDAQ:VXRT ) is possibly approaching a major achievement in its business, so we would like to shine...

  • Move Over, Tesla: There's a New Most-Held Stock on Robinhood

    Electric vehicle manufacturer Tesla has been dethroned as Robinhood's top stock. Here's what replaced it.

  • Why Amazon, Nvidia, and Salesforce Stocks Popped Today

    Shares of Amazon.com (NASDAQ: AMZN), Salesforce.com (NYSE: CRM), and Nvidia (NASDAQ: NVDA) were up 2%, 2%, and 5%, respectively, as investors rotated back into high-quality growth stocks. Barron's highlighted Amazon's attractive growth prospects -- in e-commerce, cloud computing, digital advertising, logistics, and healthcare -- in a bullish report on Friday. "Growth at Amazon Web Services is accelerating, and revenue from the unit could hit an annualized $100 billion by 2023," Savitz and Cherney said.

  • My friend is worth $10 million. As his bookkeeper, I’m asked to record illegitimate expenses. Could I be prosecuted?

    My friend has a high net worth — well over $10 million — and could easily afford these personal expenses. “I did what I was told” does not hold much sway for professionals who know the difference between illegitimate and legitimate expenses. You have blurred the boundaries between employer and friend, bookkeeping and tax dodging, and personal responsibility and professional obligation.

  • 8 Companies Keep Making Much More Money Than Anyone Imagined

    S&P 500 profits are gushing in faster than expected. But some are making a habit out of blowing away profit expectations.

  • Morgan Stanley’s Slimmon Says Buy Reopening Before Too Late

    (Bloomberg) -- When clients call Andrew Slimmon for advice on how to position their portfolios given the rapid spread of the delta variant, he tells them in no uncertain terms: Prepare for an economic recovery, and soon. Slimmon, who oversees about $7.5 billion at Morgan Stanley Investment Management, says it’s not unusual to see economic hiccups this time of year. Going forward, “people will turn a little bit more optimistic,” which bodes well for equities that have sold off due to Covid-relate

  • 10 Cheap Dividend Stocks that Will Help You Retire Before 40

    In this article, we will be taking a look at 10 cheap dividend stocks that will help you retire before 40. To skip our detailed analysis of these stocks, you can go directly to see the 5 Cheap Dividend Stocks that Will Help You Retire Before 40. Perhaps one of the main reasons one chooses to […]

  • 2 Powerful Warren Buffett Dividend Stocks You Can Buy Right Now

    Quick, can you name a famous investor who earns billions of dollars in dividends every year from publicly traded companies? If you said Warren Buffett, you've identified one star stock picker at the top of the list. Buffett and his investment vehicle Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) are huge on dividend stocks.

  • Why Wall Street Thinks BioNTech Stock Could Sink 25%

    BioNTech (NASDAQ: BNTX) might not be the best-known of the leading COVID-19 vaccine makers. The company has been largely overshadowed by its big partner Pfizer and by Moderna, at least in the U.S. However, BioNTech has been the biggest winner in the group so far this year with its shares skyrocketing more than 350%. Here's why Wall Street thinks BioNTech stock could sink 25% within the next 12 months.

  • Why Sundial Growers, Hexo, and OrganiGram Stocks Jumped Today

    There's been some good news in the Canadian cannabis sector recently, but it hasn't been reflected in several of the stocks. Shares of three Canadian growers are rebounding some today, however. The stocks of Hexo (NYSE: HEXO) and OrganiGram Holdings (NASDAQ: OGI) were up 9.3% and 7.3%, respectively, as of 2:05 p.m. EDT.